X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
MYLAN
Dec-14
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3,3973,867-   
Low Rs2,5602,725-   
Sales per share (Unadj.) Rs856.51,324.0-  
Earnings per share (Unadj.) Rs78.0159.5-  
Cash flow per share (Unadj.) Rs139.9256.7-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs739.8658.1-  
Shares outstanding (eoy) m165.74378.37-   
Bonus/Rights/Conversions BBOI-  
Price / Sales ratio x3.52.5 139.7%   
Avg P/E ratio x38.220.7 184.8%  
P/CF ratio (eoy) x21.312.8 165.8%  
Price / Book Value ratio x4.05.0 80.4%  
Dividend payout %25.70-   
Avg Mkt Cap Rs m493,6321,247,263 39.6%   
No. of employees `00022.725.0 90.7%   
Total wages/salary Rs m31,0680-   
Avg. sales/employee Rs Th6,259.020,038.0 31.2%   
Avg. wages/employee Rs Th1,369.80-   
Avg. net profit/employee Rs Th569.72,413.9 23.6%   
INCOME DATA
Net Sales Rs m141,961500,951 28.3%  
Other income Rs m1,715-2,920 -58.7%   
Total revenues Rs m143,676498,031 28.8%   
Gross profit Rs m24,722124,589 19.8%  
Depreciation Rs m10,26636,793 27.9%   
Interest Rs m63421,608 2.9%   
Profit before tax Rs m15,53763,268 24.6%   
Minority Interest Rs m0-260 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9652,660 111.4%   
Profit after tax Rs m12,92160,348 21.4%  
Gross profit margin %17.424.9 70.0%  
Effective tax rate %19.14.2 453.8%   
Net profit margin %9.112.0 75.6%  
BALANCE SHEET DATA
Current assets Rs m96,837440,402 22.0%   
Current liabilities Rs m84,199344,306 24.5%   
Net working cap to sales %8.919.2 46.4%  
Current ratio x1.21.3 89.9%  
Inventory Days Days7378 94.0%  
Debtors Days Days98107 91.0%  
Net fixed assets Rs m102,552115,894 88.5%   
Share capital Rs m82917,715 4.7%   
"Free" reserves Rs m121,7920-   
Net worth Rs m122,621249,022 49.2%   
Long term debt Rs m5,449372,014 1.5%   
Total assets Rs m218,1651,003,037 21.8%  
Interest coverage x25.53.9 649.4%   
Debt to equity ratio x01.5 3.0%  
Sales to assets ratio x0.70.5 130.3%   
Return on assets %6.28.2 76.0%  
Return on equity %10.524.2 43.5%  
Return on capital %12.913.6 94.7%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Net fx Rs m55,3150-   
CASH FLOW
From Operations Rs m21,44465,850 32.6%  
From Investments Rs m-18,404-51,931 35.4%  
From Financial Activity Rs m-3,692-17,352 21.3%  
Net Cashflow Rs m-1,144-3,433 33.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: ABBOTT INDIA  MERCK LTD  BIOCON LTD  SANOFI INDIA  ORCHID PHARMA LTD  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 23, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - AJANTA PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS